The Technical Analyst
Iterum Therapeutics PLC [ITRM]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Iterum Therapeutics PLC Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-4.43% $1.510
America/New_York / 24 apr 2024 @ 15:20
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 24.80 mill |
| EPS: | -2.96 |
| P/E: | -0.510 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 16.43 mill |
| Avg Daily Volume: | 0.626 mill |
| RATING 2024-04-23 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.510 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.09x |
| Company: PE -0.510 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-1.037 (-168.66%) $-2.55 |
| Date: 2024-04-24 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.375 - 1.645 ( +/- 8.94%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-12-22 | Dunne Michael W. | Buy | 25 000 | Ordinary Shares |
| 2023-12-18 | Dunne Michael W. | Buy | 10 000 | Ordinary Shares |
| 2023-12-01 | Puttagunta Sailaja | Sell | 8 333 | Restricted Share Units |
| 2023-12-01 | Puttagunta Sailaja | Buy | 8 333 | Ordinary Shares |
| 2023-12-01 | Puttagunta Sailaja | Sell | 2 933 | Ordinary Shares |
| INSIDER POWER |
|---|
| 76.91 |
| Last 98 transactions |
| Buy: 8 259 885 | Sell: 825 272 |
Forecast:
16:00 - $1.500
Live Trading Signals (every 1 min)
Forecast
1: 15:33 - $1.528
Forecast 2: 16:00 - $1.500
Forecast 3: 16:00 - $1.500
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.510 (-4.43% ) |
| Volume | 0.0324 mill |
| Avg. Vol. | 0.626 mill |
| % of Avg. Vol | 5.17 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ITRM
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 7 - 10:40 | buy | $1.650 | N/A | Active |
|---|
ITRM
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
Latest Press Releases
2024-03-28 07:00:00 - Press Release
Iterum Therapeutics Reports Fourth Quarter And Full Year 2023 Financial Results
- -resubmission of nda on track for early q2 24— - -cash runway into 2025, including through potential fda approval in early q4 24-- --company to host conference call today at 8:30amet-- dublin, ireland and chicago, march 28, 2024 (globe newswire) -- iterum therapeutics plc (nasdaq: itrm), a clinical-stage pharmaceutical company focused on developing next generation oral and iv antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the fourth quarter and year ended december 31, 2023. “since we announced positive topline data from our reassure trial in january, we've made significant progress in completing the new drug application (nda) for the planned resubmission early in the second quarter,” said corey fishman, iterum's chief executive officer.
2024-03-21 16:30:00 - Press Release
Iterum Therapeutics To Report Fourth Quarter And Full Year 2023 Financial Results On March 28, 2024
Dublin, ireland and chicago, march 21, 2024 (globe newswire) -- iterum therapeutics plc (nasdaq: itrm) (the company), a clinical-stage pharmaceutical company focused on developing next generation oral and iv antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the company will release its fourth quarter and full year 2023 financial results before the open of the u.s. financial markets on thursday, march 28, 2024. management will host a conference call at 8:30 a.m. et that day to discuss the company's financial results and provide an update on its business.
2024-03-15 08:00:00 - Press Release
Iterum Therapeutics To Participate In H.c. Wainwright Virtual @home Fireside Chat
Dublin, ireland and chicago, march 15, 2024 (globe newswire) -- iterum therapeutics plc (nasdaq: itrm) (iterum), a clinical-stage pharmaceutical company focused on developing next-generation oral antibiotics to treat infections caused by multi-drug resistant pathogens in community settings, announced today that the company will participate in a virtual h.c. wainwright @home fireside chat on march 21, 2024. corey fishman, iterum's chief executive officer, sailaja puttagunta, m.d., iterum's chief medical officer, and judy matthews, iterum's chief financial officer, will discuss iterum's lead program, oral sulopenem, for the treatment of adult women with uncomplicated urinary tract infections (uuti).
2024-01-30 07:00:00 - Press Release
Iterum Therapeutics Announces Positive Topline Results From Its Phase 3 Reassure Clinical Trial Of Oral Sulopenem In Uncomplicated Urinary Tract Infections
Phase 3 reassure trial met primary endpoint of non-inferiority to augmentin ® ; demonstrated statistical superiority re-submission of nda to fda expected in q2 2024 potential to be first oral penem approved in the u.s. management to host a conference call at 8:30 a.m. et today dublin and chicago , jan. 30, 2024 /prnewswire/ -- iterum therapeutics plc (nasdaq: itrm) (iterum), a clinical-stage pharmaceutical company focused on developing next-generation oral antibiotics to treat infections caused by multi-drug resistant pathogens in community settings, today announced positive topline results from its reassure (renewed assessment of sulopenem in uuti caused by resistant enterobacterales) phase 3 clinical trial comparing oral sulopenem (sulopenem etzadroxil combined with probenecid in a bilayer tablet) to oral augmentin® (amoxicillin/clavulanate) in adult women with uncomplicated urinary tract infections (uutis).
2023-12-04 08:00:00 - Press Release
Iterum Therapeutics Regains Compliance With Nasdaq Bid Price Rule
Dublin, ireland and chicago, dec. 04, 2023 (globe newswire) -- iterum therapeutics plc (nasdaq: itrm) (the “company”), a clinical-stage pharmaceutical company focused on developing next generation oral and iv antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has received a letter from the listing qualifications department of the nasdaq stock market llc (“nasdaq”) notifying the company that it has regained compliance with the minimum bid price requirement under nasdaq listing rule 5550(a)(2) (the "bid price rule") for continued listing on the nasdaq capital market.
Latest News
2024-03-28 10:08:08 - Seeking Alpha
Iterum Therapeutics plc (ITRM) Q4 2023 Earnings Call Transcript
2024-03-21 16:30:00 - GlobeNewsWire
Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
DUBLIN, Ireland and CHICAGO, March 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its fourth quarter and full year 2023 financial results before the open of the U.S. financial markets on Thursday, March 28, 2024. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company's financial results and provide an update on its business.
2024-03-07 09:00:29 - Zacks Investment Research
Iterum (ITRM) Plans Early Submission of UTI Drug NDA, Stock Up
Iterum (ITRM) stock rises as the company gears up to submit a regulatory application to the FDA seeking approval for oral sulopenem to treat adult women with uUTIs ahead of schedule.
2023-11-07 08:30:00 - GlobeNewsWire
Iterum Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on November 14, 2023
DUBLIN, Ireland and CHICAGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its third quarter 2023 financial results before the open of the U.S. financial markets on Tuesday, November 14, 2023. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company's financial results and provide an update on its business.
2023-10-12 09:15:00 - GlobeNewsWire
Iterum Therapeutics to Present Data at IDWeek 2023
DUBLIN, Ireland and CHICAGO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that three posters will be presented at the Infectious Disease Society of America's IDWeek 2023 conference taking place in Boston, MA from October 11-15, 2023.
2023-08-04 17:00:00 - GlobeNewsWire
Iterum Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 11, 2023
DUBLIN, Ireland and CHICAGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its second quarter 2023 financial results before the open of the U.S. financial markets on Friday, August 11, 2023. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company's financial results and provide an update on its business.
2023-06-12 18:23:00 - GlobeNewsWire
Iterum Therapeutics to Present Data at ASM Microbe 2023
DUBLIN, Ireland and CHICAGO, June 12, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that three posters will be presented at ASM Microbe 2023 conference.
2023-04-13 13:39:40 - Zacks Investment Research
All You Need to Know About Iterum Therapeutics PLC (ITRM) Rating Upgrade to Strong Buy
Iterum Therapeutics PLC (ITRM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2023-03-09 17:00:00 - GlobeNewsWire
Iterum Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023
DUBLIN, Ireland and CHICAGO, March 09, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its fourth quarter and fully year 2022 financial results before the open of the U.S. financial markets on Thursday, March 16, 2023. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company's financial results and provide an update on its business.
2022-11-10 11:42:07 - Seeking Alpha
Iterum Therapeutics plc (ITRM) Q3 2022 Earnings Call Transcript
Iterum Therapeutics plc (NASDAQ:ITRM ) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Louise Barrett – Senior Vice President-Legal Affairs Corey Fishman – Chief Executive Officer Judy Matthews – Chief Financial Officer Conference Call Participants Ed Acre – H.C. Wainwright Operator Ladies and gentlemen, welcome to the Iterum Therapeutics Third Quarter 2022 Financial Results Call.